Immunotherapy company Biopharmaceutical New Technologies or BioNTech SE announced Wednesday a profit for the fourth quarter compared to a loss last year, driven by the continued global delivery of its COVID-19 vaccine. The company also reiterated its COVID-19 vaccine revenue guidance for the full-year 2022.
from RTT - Earnings https://ift.tt/rM1q6Re
via IFTTT
No comments:
Post a Comment